GLUCAGEN
LOE ApproachingNDAINTRAMUSCULAR, INTRAVENOUSPOWDERPriority Review
Approved
Jun 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
Priority Review
GLUCAGEN by Novo Nordisk is clinical pharmacology glucagon increases blood glucose concentration and is used in the treatment of severe hypoglycemia. First approved in 1998.
Drug data last refreshed 23h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GLUCAGEN is a glucagon injection (powder formulation) approved for emergency treatment of severe hypoglycemia in patients with diabetes. It works by stimulating hepatic glycogenolysis to rapidly increase blood glucose concentration. The drug is administered parenterally (IM, IV, or SC) and achieves peak glucose levels within 13-30 minutes.
$5MPart D
LOE ApproachingProduct approaching loss of exclusivity with modest Part D spending; expect reduced team investment and focus shift to post-LOE defensive positioning.
Mechanism of Action
CLINICAL PHARMACOLOGY Glucagon increases blood glucose concentration and is used in the treatment of severe hypoglycemia. Glucagon acts only on liver glycogen, converting it to glucose. Glucagon administered through a parenteral route relaxes smooth muscle of the stomach, duodenum, small bowel, and…
Indications
Worked on GLUCAGEN at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.